BioNTech SE — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a Q4-only filing; separate fourth-quarter financial results are not clearly provided in the supplied text. Financial statements are prepared under IFRS and reported in euros.
Financial performance and position
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenue | €17.31bn | €18.98bn | -9% |
| Operating income | €12.64bn | €15.28bn | -17% |
| Profit before tax | €12.95bn | €15.05bn | -14% |
| Net profit | €9.43bn | €10.29bn | -8% |
| Basic / diluted EPS | €38.78 / €37.77 | €42.18 / €39.63 | Lower |
| Operating cash flow | €13.58bn | €0.89bn | Higher |
| Cash and cash equivalents | €13.88bn | €1.69bn | Higher |
Commercial revenue was €17.19bn, including €17.15bn from the COVID-19 vaccine. This concentration makes results highly dependent on Comirnaty. Revenue from the vaccine declined mainly with slightly lower demand. Pfizer-partner gross-profit share and sales milestones contributed €12.74bn, down from €14.83bn in 2021.
R&D expense rose 62% to €1.54bn; general and administrative expense rose 70% to €484.7m. Cost of sales increased 3% to €3.00bn. Approximate operating margin was 73% (2021: 81%); net margin was about 54% in both years.
Operating cash flow benefited from a €4.37bn decrease in trade and other receivables, including timing of Pfizer profit-share settlements. A €1.82bn settlement for Q3 2022 was received in January 2023. Investing cash outflow was €35.3m; financing cash outflow was €1.42bn, including €986.4m of repurchases and a €484.3m dividend.
Year-end total liabilities were €3.22bn, including €212.2m of lease liabilities, loans and borrowings; the convertible note was redeemed in March 2022. The filing reports no separate conventional debt total beyond these figures.
Changes, outlook and material items
- Revenue and operating income fell from 2021, while cash and operating cash flow increased substantially. Vaccine revenue remained the dominant source of income.
- Inventory write-offs and provisions for redundant contract manufacturing capacity affected 2022. Inventory write-offs and reserves related to the COVID-19 vaccine were €484.6m; €850.0m of sales to collaboration partners reflected manufacturing variances.
- Management expects COVID-19 vaccine demand and revenue to decline as the virus becomes endemic. It anticipated that commercial buyers would assume a larger purchasing role in some markets; in the U.S., the transition was expected in Q3 2023. No numerical 2023 revenue guidance is clearly provided in the supplied text.
- BioNTech plans substantial R&D and organizational investment. It reported 25-plus clinical-stage candidates and more than 30 research projects, and targeted readiness for initial oncology launches from 2026 onward.
- Management reported favorable preliminary clinical updates in several programs, including BNT211 CAR-T activity in a small study and a pancreatic cancer vaccine study. These are early findings, not established efficacy or approval.
- Important legal contingencies include patent suits involving Alnylam, CureVac and Moderna and product-liability claims. Management said outcomes were uncertain and could not reliably estimate potential losses; no provision was recorded for these patent matters.
- Other notable exposures include a €235.5m provision for redundant CMO capacity and disclosed internal reviews concerning German wage-tax/social-security withholding and customs compliance. The company notified relevant authorities; no administrative or criminal proceedings had been opened for those matters as of the report date.
- The annual financial statements received an unqualified audit opinion; the auditor identified revenue recognition for Pfizer’s vaccine sales and claims/legal contingencies as critical audit matters. Management and auditor reported effective internal control over financial reporting as of year-end.
Investor verification priorities
- Check final Pfizer sales, costs and profit-share data against BioNTech’s reported estimates; the auditor highlighted estimation uncertainty, particularly for ex-U.S. sales and costs.
- Assess the pace of COVID-19 demand decline, 2023 order timing, commercial-channel transition and possible inventory or manufacturing-capacity charges.
- Track cash conversion and receivables collection, including the timing of partner settlements, rather than relying on reported profit alone.
- Monitor patent litigation, product-liability claims, the CMO provision, and the outcome and potential financial effects of tax, social-security and customs reviews.
- Evaluate whether higher R&D spending and pipeline progress translate into later-stage data, approvals and commercial products; verify the status and economics of planned acquisitions and collaborations.